1. Home
  2. UAN vs PHAR Comparison

UAN vs PHAR Comparison

Compare UAN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$132.15

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$16.38

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UAN
PHAR
Founded
2007
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
UAN
PHAR
Price
$132.15
$16.38
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$38.33
AVG Volume (30 Days)
62.0K
6.4K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
7.91%
N/A
EPS Growth
61.98
N/A
EPS
4.72
N/A
Revenue
$606,038,000.00
N/A
Revenue This Year
N/A
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
$28.56
$3,041.22
Revenue Growth
15.36
N/A
52 Week Low
$80.96
$8.69
52 Week High
$139.50
$21.34

Technical Indicators

Market Signals
Indicator
UAN
PHAR
Relative Strength Index (RSI) 53.48 45.22
Support Level $119.03 $15.96
Resistance Level $139.42 $17.28
Average True Range (ATR) 4.92 0.31
MACD 0.28 -0.11
Stochastic Oscillator 61.38 8.93

Price Performance

Historical Comparison
UAN
PHAR

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: